Diabetes mellitus and progression of rigidity and gait disturbance in older persons
Abstract
Background: Parkinsonian-like signs, including rigidity, gait disturbance, and bradykinesia, are common and progressive in old age and are associated with morbidity and mortality. Few risk factors for these signs have been identified. Diabetes mellitus, also a common chronic condition in old age and known to be associated with physical and neurologic disability, may be associated with parkinsonian-like signs.
Objective: To examine the relation of diabetes to four parkinsonian-like signs.
Methods: Participants were 822 older Catholic clergymen and women who were without clinically diagnosed Parkinson disease or dementia at baseline. For up to 9 years, they had uniform annual evaluations, which included a modified version of the motor portion of the Unified Parkinson’s Disease Rating Scale, from which previously established measures of four specific parkinsonian-like signs were derived. Participants were evaluated for the presence of diabetes, based on direct medication inspection and history.
Results: Diabetes was present in 128 (15.6%) participants. In random effects models controlling for age, sex, and education, diabetes was associated with worsening rigidity (p < 0.01) and gait (p < 0.05), over an average of 5.6 years of follow-up, but not with change in bradykinesia or tremor. The presence of stroke did not substantially affect the association of diabetes with rigidity but reduced the association of diabetes with gait to a trend (p = 0.08).
Conclusion: Diabetes may be a previously unrecognized risk factor for progression of parkinsonian-like signs in older persons.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Richards M, Stern Y, Marder K, Cote L, Mayeux R. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson’s disease and normal elderly individuals. Ann Neurol. 1993; 33: 267–274.
2.
Kaye JA, Oken BS, Howieson DB, Howieson J, Holm LA, Dennison K. Neurologic evaluation of the optimally healthy oldest old. Arch Neurol. 1994; 51: 1205–1211.
3.
Bennett DA, Shannon KM, Beckett LA, Wilson RS. Dimensionality of parkinsonian signs in aging and Alzheimer’s disease. J Gerontol Med Sci. 1999; 54A: M191–M196.
4.
Mitchell SL, Rockwood K. Defining parkinsonism in the Canadian Study of Health and Aging. Int Psychogeriatr. 2001; 13 (suppl 1): 107–113.
5.
Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002; 55: 25–31.
6.
Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996; 334: 71–76.
7.
Bennett DA, Beckett LA, Wilson RS, Murray AM, Evans DA. Parkinsonian signs and mortality from Alzheimer’s disease. Lancet. 1998; 351: 1631.
8.
Mitchell SL, Rockwood K. The association between parkinsonism, Alzheimer’s disease, and mortality: a comprehensive approach. J Am Geriatr Soc. 2000; 48: 422–425.
9.
Wilson RS, Schneider JA, Beckett LA, Evans DA, Bennett DA. Progression of gait disorder and rigidity and risk of death in older persons. Neurology. 2002; 58: 1815–1819.
10.
Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol. 2003; 60: 539–544.
11.
Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonism and loss of cognitive function in Alzheimer disease. Arch Neurol. 2000; 57: 855–860.
12.
Tison F, Lecaroz J, Letenneur L, Dartigues JF. Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions. Clin Neuropharmacol. 1999; 22: 5–10.
13.
Rocca WA, Bower JH, McDonnell SK, Peterson BJ, Maraganore DM. Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology. 2001; 57: 462–467.
14.
Engel LS, Checkoway H, Keifer MC, et al. Parkinsonism and occupational exposure to pesticides. Occup Environ Med. 2001; 58: 582–589.
15.
Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology. 2003; 61: 24–28.
16.
National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2000. MD: U.S. Department of Health and Human Services, NIH, 2002.
17.
Palumbo PJ, Elveback LR, Whisnant JP. Neurologic complications of diabetes mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol. 1978; 19: 593–601.
18.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43: 817–824.
19.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993; 36: 150–154.
20.
Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke. 1994; 25: 951–957.
21.
Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke. 1994; 25: 1977–1984.
22.
Rodriguez BL, Abbott RD, Fujimoto W, et al. The American Diabetes Association and World Health Organization classifications for diabetes: their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese–American men. Diabetes Care. 2002; 25: 951–955.
23.
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999; 53: 1937–1942.
24.
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu–Asia Aging Study. Diabetes. 2002; 51: 1256–1262.
25.
Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer’s disease and decline in cognitive function. Arch Neurol. 2004; 61: 661–666.
26.
Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992; 7: 2–13.
27.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34: 939–944.
28.
Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology. 2003; 60: 1082–1088.
29.
Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989; 39: 1159–1165.
30.
Medi-Span, Inc. Master drug database documentation manual. Indianapolis: Medi-Span, 1995.
31.
Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses’ ratings of parkinsonian signs with a modified Unified Parkinson’s Disease Rating Scale. Neurology. 1997; 49: 1580–1587.
32.
Fahn S, Elton RL. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson’s disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987: 153–163.
33.
Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology. 1990; 40: 897–900.
34.
Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999; 56: 98–102.
35.
Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med. 2000; 160: 174–180.
36.
Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001; 24: 366–370.
37.
Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001; 56: 42–48.
38.
Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonian signs in Alzheimer’s disease. Neurology. 2000; 54: 1284–1289.
39.
Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol. 2002; 441: 1–14.
40.
Borg MA, Borg WP, Tamborlane WV, Brines ML, Shulman GI, Sherwin RS. Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats. Diabetes. 1999; 48: 584–587.
41.
Simpson IA, Appel NM, Hokari M, et al. Blood–brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem. 1999; 72: 238–247.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: December 13, 2003
Accepted: May 14, 2004
Published online: September 27, 2004
Published in print: September 28, 2004
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Studies on alpha-synuclein and islet amyloid polypeptide interaction, Frontiers in Molecular Biosciences, 10, (2023).https://doi.org/10.3389/fmolb.2023.1080112
- Intelligent Care Management for Diabetic Foot Ulcers: A Scoping Review of Computer Vision and Machine Learning Techniques and Applications, Journal of Diabetes Science and Technology, (2023).https://doi.org/10.1177/19322968231213378
- A Systematic Review on Functional Near-Infrared Spectroscopy Concurrent With Quantitative Balance Assessment, IEEE Access, 11, (66641-66671), (2023).https://doi.org/10.1109/ACCESS.2023.3291804
- Association of diabetes mellitus with gait and falls in community-dwelling older adults: Serial mediation of vision and cognition, Archives of Gerontology and Geriatrics, 104, (104827), (2023).https://doi.org/10.1016/j.archger.2022.104827
- The association of comorbidity with Parkinson's disease-related hospitalizations, Parkinsonism & Related Disorders, 104, (123-128), (2022).https://doi.org/10.1016/j.parkreldis.2022.10.012
- Factors associated with motor severity in vascular parkinsonism with normal dopamine transporter imaging, Parkinsonism & Related Disorders, 94, (99-103), (2022).https://doi.org/10.1016/j.parkreldis.2021.11.033
- Advancements and future directions in research of the roles of insulin in amyloid diseases, Biophysical Chemistry, 281, (106720), (2022).https://doi.org/10.1016/j.bpc.2021.106720
- Biomechanics of the ankle-foot unit: derangements and radiological signs, The Essentials of Charcot Neuroarthropathy, (1-45), (2022).https://doi.org/10.1016/B978-0-323-99352-4.00012-7
- Insights into the Mechanistic Perspective Effect of Insulin on the Nonamyloidogenic Component (NAC) and α-Synuclein Aggregation, ACS Chemical Neuroscience, 12, 17, (3266-3276), (2021).https://doi.org/10.1021/acschemneuro.1c00445
- Parkinsonism, Principles and Practice of Movement Disorders, (82-120.e21), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00004-4
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.